Prostate cancer diagnostic guidelines aim to minimize over-diagnosis of clinically insignificant prostate cancer (Gleason6/GG1). The clinical question before us is how do we enable the best balance, helping to increase compliance with the biopsy recommendation for patients at higher-risk while providing greater assurance for low-risk patients in an informed shared decision to defer biopsy? There is a vital need to understand better how mpMRI and the various biomarkers can be integrated into the prostate cancer diagnostic algorithm. All risk stratification tools, including mpMRI or biomarkers, have individual strengths and limitations. Complementary risk assessment methods can balance out limitations and leverage the respective strengths for stronger clinical assessment. This webinar discusses how biomarkers, specifically the ExoDx Prostate Test, might be considered in combination with MRI imaging in men considering a diagnostic prostate biopsy.